ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "race/ethnicity"

  • Abstract Number: 1024 • ACR Convergence 2023

    Relationship Between Race and Ethnicity, Time to Diagnosis, and Disease Activity for Children with Juvenile Idiopathic Arthritis in the CARRA Registry

    Sarah McGuire1, Tania Atanassova2, Joanna Madej2, Manuel Jimenez2, Daniel Horton1 and for the CARRA TMJ Arthritis Workgroup3, 1Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 2Rutgers, Robert Wood Johnson Medical School, New Brunswick, NJ, 3Childhood Arthritis and Rheumatology Research Alliance, Washington, DC

    Background/Purpose: Compared to non-Hispanic White children, Black children diagnosed with juvenile idiopathic arthritis (JIA) have more severe disease at diagnosis and worse outcomes, such as…
  • Abstract Number: 2088 • ACR Convergence 2023

    Room for Racial and Ethnic Diversity in Adult Rheumatology Fellowship Pipeline

    Bessie Roca Loor1, Maya Pandit2, Tracey Wright3 and Mill Etienne4, 1New York Medical College, Yonkers, NY, 2Columbia University, New York, NY, 3UT Southwestern, Dallas, TX, 4New York Medical College, Valhalla, NY

    Background/Purpose: The 2015 American College of Rheumatology Workforce study showed 8 of 1011 adult rheumatologists identified as Black, 85 Hispanic and 3 American Indian or…
  • Abstract Number: 0153 • ACR Convergence 2023

    Diminished Vibration Perception and Greater Pressure Pain Sensitivity Are Associated with Worse Knee Osteoarthritis Outcomes Across Sex and Race

    Chris Lane1, Louise Thoma2, Carolina Alvarez3, Deborah Givens4, Amanda Nelson4, Adam Goode5, Kharma Foucher6 and Yvonne Golightly7, 1UNC Chapel Hill, Chapel Hill, NC, 2University of North Carolina, Chapel Hill, NC, 3University of North Carolina at Chapel Hill, Miami, FL, 4University of North Carolina at Chapel Hill, Chapel Hill, NC, 5Duke University, Durham, NC, 6University of Illinois at Chicago, Chicago, IL, 7University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Sex and race differences have been observed in clinical outcomes such as patient-reported pain and function in adults with knee OA. However, few studies…
  • Abstract Number: 1025 • ACR Convergence 2023

    Embedding Treat to Target Principles in Rheumatoid Arthritis Patient Education in Routine Care of Ethnic Minority Patients

    Sharon Dowell1, Mercedes Quinones2, Tahereh Jamshidi3, Ilona Jileaeva4, Oshoze Kadiri4 and Gail Kerr5, 1NEA Baptist Memorial Hospital, Jonesboro, AR, 2Washington DC VA Medical Center, Bethesda, MD, 3Howard University Hospital, Bethesda, MD, 4Howard University, Washington, DC, 5Washington DC VAMC/Georgetown and Howard Universities, Washington, DC

    Background/Purpose: A successful treat to target (T2T) strategy in ethnic minority (EM) patients with rheumatoid arthritis (RA) could improve patient outcomes and help reduce healthcare…
  • Abstract Number: 2347 • ACR Convergence 2023

    Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus by Race and Ethnicity: A Large Post Hoc Integrated Analysis of Five Clinical Trials

    Saira Sheikh1, Amit Saxena2, Angela Carroll3, Christine Henning3, Julia HN Harris4, Bernard Rubin5, David D'Cruz6 and Alvin F Wells7, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2New York University Grossman School of Medicine, Rheumatology, New York, NY, 3GlaxoSmithKline, US Medical Affairs, Durham, NC, 4GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, 5GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, 6Guy’s Hospital, Louise Coote Lupus Unit, London, United Kingdom, 7Advocate Health Department of Rheumatology, Franklin, WI

    Background/Purpose: Belimumab (BEL) is approved for the treatment of active SLE, and lupus nephritis, with standard therapy.1 The prevalence and severity of SLE tend to…
  • Abstract Number: 003 • 2023 Pediatric Rheumatology Symposium

    Inflammation or Infection? Understanding Linguistic and Cultural Nuances Impacting the Care of Somali Children with Juvenile Idiopathic Arthritis

    Emily Hause, Abdirazak Ali and Muna Sunni, University of Minnesota, Minneapolis, MN

    Background/Purpose: Data regarding the linguistic and cultural factors impacting the Somali patient experience and understanding with regards to juvenile idiopathic arthritis (JIA) are limited. We…
  • Abstract Number: 022 • 2023 Pediatric Rheumatology Symposium

    Narrative Medicine and Pediatric Rheumatology: Addressing Burnout and Bias

    aviya lanis, Natalie Rosenwasser and Esi Morgan, Seattle Children's Hospital, Seattle, WA

    Background/Purpose: Burnout, a syndrome of emotional exhaustion and depersonalization, adversely impacts healthcare. This can result in mood disturbances, poor patient and provider satisfaction and high…
  • Abstract Number: 101 • 2023 Pediatric Rheumatology Symposium

    Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity

    Susan Kim1, Rebecca Olveda2 and Jessica Neely2, 1UCSF Benioff Children's Hospital, San Francisco, CA, 2UCSF, San Francisco, CA

    Background/Purpose: Previous studies in juvenile dermatomyositis (JDM) have shown that patients from minoritized ethnicities and those with lower family income are more likely to have…
  • Abstract Number: 137 • 2023 Pediatric Rheumatology Symposium

    Geographic Mapping of Adolescents with Rheumatic Disease: Racial and Ethnic Diversity by Texas County

    Kristina Ciaglia1, Chan-hee Jo2, Yuhan Ma2, Tracey Wright3 and Lorien Nassi1, 1University of Texas Southwestern, Dallas, TX, 2Scottish Rite Hospital for Children, Dallas, TX, 3University of Texas Southwestern, Scottish Rite Hospital for Children, Dallas, TX

    Background/Purpose: Rheumatic disease disproportionately impacts specific racial and ethnic groups frequently, resulting in health care inequities. Health care disparities are prevalent within certain geographic areas…
  • Abstract Number: 0089 • ACR Convergence 2022

    Racial Disparities in Rheumatology Clinical Trials

    Pushti Khandwala1, Anila Hussain2 and Irene Tan3, 1Einstein Medical Center Philadelphia, Glen Mills, PA, 2Crozer Chester Medical Center, Glen Mills, PA, 3Einstein Medical Center Philadelphia, Philadelphia, PA

    Background/Purpose: Healthcare disparities exist in patients living with rheumatologic diseases. Factors contributing to disparities include age, sex, race, or sociodemographic variables, each playing a crucial…
  • Abstract Number: 0488 • ACR Convergence 2022

    Discrepancies in Temporal Artery Biopsy Positivity Rate Among White and Black Patients Suspected of Having Giant Cell Arteritis: Experience from a Tertiary Academic Medical Center

    Raj Vachhani1, Peng Li2, Mehdi Tavakoli2, Lanning Kline2 and Angelo Gaffo2, 1University of Alabama at Birmingham, Homewood, AL, 2University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: A prior study evaluated incidence rates of biopsy proven giant cell arteritis (GCA) among black and white patients, concluding that GCA occurs at a…
  • Abstract Number: 1766 • ACR Convergence 2022

    COVID-19 Cutaneous and Systemic Manifestations Among Race: A Systematic Review and Meta-Analysis

    Angie El-Said1, Areeb Ahmad2, Massimo Valenti3, Neel K. Shah1, Susana Soto1 and Shazia Beg4, 1University of Central Florida College of Medicine, Orlando, FL, 2University of Central Florida, Orlando, FL, 3Sapienza University of Rome, School of Medicine, Rome, Italy, 4UCF, Orlando, FL

    Background/Purpose: Although various systemic and dermatologic manifestations associated with COVID-19 have been reported in the literature, investigations of how these manifestations vary by race remain…
  • Abstract Number: 0090 • ACR Convergence 2022

    Lack of Racial and Ethnic Diversity in Clinical Trials of Psoriatic Arthritis

    Niti Goel, TrialSpark, Duke University, Durham, NC

    Background/Purpose: Participant diversity in clinical trials of therapeutics in rheumatology is important to evaluate to better understand how individuals of different races and ethnicities might…
  • Abstract Number: 0521 • ACR Convergence 2022

    Examination of Differential Response to Treatment with Mycophenolate Mofetil in Black and White Patients with Systemic Sclerosis

    Lauren Smith1, Jamie Perin2, Adrianne Woods2, Fredrick Wigley3, Laura Hummers4 and Ami Shah5, 1Johns Hopkins, District Heights, MD, 2John Hopkins University, Baltimore, MD, 3Johns Hopkins University, Baltimore, MD, 4Johns Hopkins Univerisity, Baltimore, MD, 5Johns Hopkins Rheumatology, Baltimore, MD

    Background/Purpose: Black patients with systemic sclerosis (SSc) develop SSc at a younger age and have more severe disease than White patients, including a higher prevalence…
  • Abstract Number: 1793 • ACR Convergence 2022

    Prevalence of HLA B*5801 Allele Among African American Patients with Gout in an Academic Health Center

    Namitha Nair, Dipanjan Debnath and FLORINA CONSTANTINESCU, MedStar Washington Hospital Center, Washington, DC

    Background/Purpose: The presence of the HLA-B*5801 allele is strongly associated with Allopurinol Hypersensitivity Syndrome (AHS) manifesting as severe cutaneous adverse reactions (SCARs) like Drug rash…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 14
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology